Transcription Factor Screening for Stem Cell Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentiating human pluripotent stem cells into diverse cell types, such as neural and cardiomyocytes, are labor-intensive, time-consuming, and often produce non-homogeneous cell populations, limiting the scalability and efficiency of cellular engineering and disease modeling.
Innovation Solution
A screening platform and method for systematically identifying transcription factors (TFs) that drive differentiation of pluripotent stem cells into target cell types, including neural progenitors and cardiomyocytes, using overexpression and pooled screening approaches to generate homogeneous cell populations efficiently.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If exogenous growth factors or small molecules are used for differentiation, then cell type diversity can be achieved, but the process becomes labor-intensive and time-consuming
Solution Approach 1:
The patent changes the fundamental parameter of differentiation control from exogenous small molecules/growth factors to endogenous transcription factors. By overexpressing specific TFs (e.g., NEUROG2 for neurons, PAX6 for radial glia), the system achieves rapid differentiation (days vs. months) while maintaining cell type diversity through selective TF expression patterns
Solution Approach 2:
The patent replaces the mechanical/manual process of optimizing exogenous factor dosages and timing with a genetic approach where TF overexpression is achieved through viral transduction. This substitution eliminates labor-intensive optimization steps while maintaining the ability to generate diverse cell types
2Adaptability or versatility
If exogenous growth factors or small molecules are used for differentiation, then various cell types can be generated, but the methods produce non-homogeneous cell populations
Solution Approach 1:
By switching from small molecule-mediated differentiation to TF overexpression, the patent achieves more uniform cellular responses. The genetic approach ensures consistent TF delivery and expression across cell populations, resulting in homogeneous cell types with defined identities (e.g., uniform radial glia or neurons) rather than heterogeneous mixtures
3Measurement precision
If arrayed screens are used to discover transcription factors, then individual TF effects can be tested, but scalability is limited to 5-25 TFs
Solution Approach 1:
The patent merges individual TF screening into a pooled approach where hundreds of barcoded TFs are tested simultaneously in a single culture. Each TF carries a unique barcode, allowing parallel assessment of thousands of TFs through next-generation sequencing, dramatically increasing throughput from 5-25 to hundreds of TFs per experiment
Solution Approach 2:
The patent uses barcode sequences as informational copies of TF identity. Instead of physically separating and testing each TF individually, the barcode copy allows high-throughput identification of which TFs drive differentiation, maintaining measurement precision while enabling massive parallel screening
4Productivity
If pooled screening with barcodes is used, then screening scalability is dramatically increased, but individual perturbation testing becomes less direct
Solution Approach 1:
The patent uses barcode sequences as informational copies that link each TF to its identity. This copying approach allows the complex pooled screen to be decoded through sequencing, where the barcode copy reveals which TF caused which differentiation outcome, managing system complexity through information encoding
Solution Approach 2:
The patent implements feedback through barcode sequencing results that identify successful TFs. The sequencing data provides feedback on which barcoded TFs drove differentiation, allowing researchers to select and validate top candidates while maintaining the scalability benefits of the pooled approach
Data Source
AI summary
The subject matter disclosed herein is generally directed to methods of differentiating pluripotent cells into target cell types and screening platforms for systematically identifying transcription factors (TFs) that drive differentiation of pluripotent cells into target cell types. Also disclosed is a high-throughput multiplex screening platform. Also disclosed are in vitro models for neural progenitor cells and cardiomyocytes.